TY - JOUR
T1 - Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes
AU - Jain, Preetesh
AU - Kantarjian, Hagop
AU - Sasaki, Koji
AU - Jabbour, Elias
AU - Dasarathula, Jyothsna
AU - Nogueras Gonzalez, Graciela
AU - Verstovsek, Srdan
AU - Borthakur, Gautam
AU - Wierda, William
AU - Kadia, Tapan
AU - Dellasala, Sara
AU - Pierce, Sherry
AU - Ravandi, Farhad
AU - O'Brien, Susan
AU - Cortes, Jorge
N1 - Publisher Copyright:
© 2016 John Wiley & Sons Ltd.
PY - 2016/4/1
Y1 - 2016/4/1
N2 - This study assessed the relevance of 2013 European LeukaemiaNet (ELN) response categories on patients treated with common frontline tyrosine kinase inhibitors (TKI) in chronic myeloid leukaemia in chronic phase (CML-CP). Four hundred and eighty-seven patients treated with imatinib (400 mg; IM 400, n = 70; 800 mg; IM800, n = 201), dasatinib (n = 107) or nilotinib (n = 109) were analysed. Intention to treat (ITT) analysis indicated that the proportion of patients falling into optimal, warning and failure ELN categories were 89%, 6%, 6% at 3 months, 78%, 17% and 6% at 6 months, and 75%, 13% and 13% at 12 months, respectively. Rates of optimal response at 3 months were 75% for IM400, 90% for IM800, 89% for dasatinib and 97% for nilotinib; 41%, 80%, 86% and 89% at 6 months; and 47%, 77%, 76% and 87% at 12 months, respectively. Patients achieving optimal response had longer eventfree (EFS), failurefree (FFS), transformationfree (TFS) and overall survival (OS) compared to warning and failure responses at all-time points. Treatment with imatinib 800, dasatinib or nilotinib predicted for achieving an optimal response. Optimal response predicted for significantly longer EFS, FFS, TFS and OS at 3, 6 and 12 months, irrespective of the TKI modality used. ELN response categories reliably predicted outcomes in CML patients receiving commonly used TKIs.
AB - This study assessed the relevance of 2013 European LeukaemiaNet (ELN) response categories on patients treated with common frontline tyrosine kinase inhibitors (TKI) in chronic myeloid leukaemia in chronic phase (CML-CP). Four hundred and eighty-seven patients treated with imatinib (400 mg; IM 400, n = 70; 800 mg; IM800, n = 201), dasatinib (n = 107) or nilotinib (n = 109) were analysed. Intention to treat (ITT) analysis indicated that the proportion of patients falling into optimal, warning and failure ELN categories were 89%, 6%, 6% at 3 months, 78%, 17% and 6% at 6 months, and 75%, 13% and 13% at 12 months, respectively. Rates of optimal response at 3 months were 75% for IM400, 90% for IM800, 89% for dasatinib and 97% for nilotinib; 41%, 80%, 86% and 89% at 6 months; and 47%, 77%, 76% and 87% at 12 months, respectively. Patients achieving optimal response had longer eventfree (EFS), failurefree (FFS), transformationfree (TFS) and overall survival (OS) compared to warning and failure responses at all-time points. Treatment with imatinib 800, dasatinib or nilotinib predicted for achieving an optimal response. Optimal response predicted for significantly longer EFS, FFS, TFS and OS at 3, 6 and 12 months, irrespective of the TKI modality used. ELN response categories reliably predicted outcomes in CML patients receiving commonly used TKIs.
KW - Chronic myeloid leukaemia
KW - ELN
KW - European LeukaemiaNet
KW - Response in CML
KW - Tyrosine kinase inhibitor (TKI)
UR - http://www.scopus.com/inward/record.url?scp=84957698831&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84957698831&partnerID=8YFLogxK
U2 - 10.1111/bjh.13936
DO - 10.1111/bjh.13936
M3 - Article
C2 - 26846160
AN - SCOPUS:84957698831
SN - 0007-1048
VL - 173
SP - 114
EP - 126
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 1
ER -